While some studies have identified mechanisms of APR-246 action beyond direct p53 binding in cancers [66], our data demonstrate that one of its primary modes of action is targeting the p53 pathway [18], as APR-246 was largely ineffective in p53 null cells compared to HO-3867. Here, TP53 is linked to cancer.